Tofacitinib citrate
|
- ₹12297.2 - ₹49589.33
- Product name: Tofacitinib citrate
- CAS: 540737-29-9
- MF: C16H20N6O.C6H8O7
- MW: 504.497
- EINECS:638-826-4
- MDL Number:MFCD11616529
- Synonyms:1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);CP-690550 (Tofacitinib citrate);CP 690500-10;CP 690550-10;1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-, citrate;1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE;Tofacitinib citrate, >=98%;1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
2 prices
Selected condition：
Brand
- Sigma-Aldrich(India)
Package
- 5MG
- 25MG
- ManufacturerSigma-Aldrich(India)
- Product numberPZ0017
- Product descriptionTofacitinib citrate ≥98% (HPLC)
- Packaging5MG
- Price₹12297.2
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberPZ0017
- Product descriptionTofacitinib citrate ≥98% (HPLC)
- Packaging25MG
- Price₹49589.33
- Updated2022-06-14
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | PZ0017 | Tofacitinib citrate ≥98% (HPLC) | 5MG | ₹12297.2 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PZ0017 | Tofacitinib citrate ≥98% (HPLC) | 25MG | ₹49589.33 | 2022-06-14 | Buy |
Properties
Melting point :201 °C (decomp)
storage temp. :room temp
solubility :DMSO: soluble5mg/mL (clear solution; warmed)
form :powder
color :white to beige
InChIKey :SYIKUFDOYJFGBQ-YLAFAASESA-N
SMILES :C1[C@@H](C)[C@@H](N(C2C3=C(NC=C3)N=CN=2)C)CN(C(CC#N)=O)C1.C(C(=O)O)C(C(=O)O)(O)CC(O)=O |&1:1,3,r|
storage temp. :room temp
solubility :DMSO: soluble5mg/mL (clear solution; warmed)
form :powder
color :white to beige
InChIKey :SYIKUFDOYJFGBQ-YLAFAASESA-N
SMILES :C1[C@@H](C)[C@@H](N(C2C3=C(NC=C3)N=CN=2)C)CN(C(CC#N)=O)C1.C(C(=O)O)C(C(=O)O)(O)CC(O)=O |&1:1,3,r|
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|
Description
Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks. Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.
More related product prices
918504-65-1 Crizotinib Sunitinib Malate 1195765-45-7 Vorinostat CIS-N-BENZYL-3-METHYLAMINO-4-METHYL-PIPERIDINE BIS-(HYDROCHLORIDE) N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine dihydrochloride 3-bis(4-Methylbenzoyloxy)succinate) Azathioprine N-Hydroxysuccinimide 5-(5-Chlorosulfonyl-2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one Ruxolitinib 1-Benzyl-4-methyl-piperidin-3-one hydrochloride 6-AMINO-5(2,2-DIETHOXYETHYL)-4-HYDROXY-2-MERCAPTOPYRIMIDINE Benzyl chloride Malonyl chloride 10132-07-7 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine BENZYL ETHYL ETHERRelated product price
- Crizotinib
₹13174.03 - Sunitinib Malate
₹15891.1-63477.8 - Vorinostat
₹10110.55-40983.45